In a move reflecting both scientific curiosity and a growing acceptance of psychedelics in research, the Drug Enforcement Administration (DEA) has finalized its production quotas for 2026, significantly increasing the amounts of certain mind-altering substances that can legally be produced in the United States.
The final rule, published this week, raises quotas for psilocybin, psilocyn, and DMT, allowing researchers to explore their potential as treatments for conditions such as depression and post-traumatic stress disorder (PTSD). Psilocybin production, for example, is set to jump from 40,000 grams in the initial proposal to 50,000 grams, while psilocyn quotas more than doubled from 36,000 grams in 2025 to 80,000 grams this year. DMT production will also rise to 25,000 grams.
Other compounds, including MDMA-like methylone and 5-MeO-DMT, saw dramatic increases as well, reflecting an ongoing trend of expanding research into therapeutic psychedelics. For instance, methylone’s quota has grown from a modest 5,200 grams in 2025 to 30,000 grams in 2026, while 5-MeO-DMT jumped from 11,000 grams to 30,000 grams.
According to the DEA, these adjustments are based on public feedback, scientific demand, and anticipated research and industrial needs. The agency emphasized that the new quotas aim to support medical and scientific research while maintaining lawful production standards.
While cannabis, THC, ibogaine, MDMA, LSD, and mescaline quotas remain unchanged, the latest increases for psychedelics underscore the federal government’s recognition of their growing role in mental health research. With these new quotas in place, 2026 promises to be another year of expanded exploration in the world of psychedelics—legally, at least.
Dabbin-Dad Newsroom
DEA Says “More, Please!”—Psychedelics Production Gets a 2026 Boost
If you liked this post, say thanks by sharing it
